Cancer Treatment News and Research

RSS

Risks outweigh benefits of shark cartilage as anti-cancer treatment

As a treatment for advanced cancer, shark cartilage fails to benefit patients and its adverse effects lead to poor compliance.

23 May 2005

Being married or in a relationship significantly improves quality of life for prostate cancer patients following treatment

Partnered men reported better psychosocial and spiritual well-being, suffered fewer adverse effects from treatment and had less fear and anxiety about their cancer coming back than did their single counterparts, the study found.

23 May 2005

Market forces alone are not sufficient to produce new drugs needed for children with cancer

Faced with "a near absence of research in pediatric cancer drug discovery," the IOM report recommends forming new public-private partnerships among government, industry, researchers, advocacy groups and other parties to lead research and development.

23 May 2005

New drug combination prevents breast cancer growth pre-surgery

A new type of drug originally developed for lung cancer can reduce the size of breast cancer tumours when taken in combination with other drugs.

17 May 2005

Antibody combined with cancer drug shows promise against breast tumors

An antibody that targets the blood vessels nourishing tumors significantly reduced breast cancer formation and growth in mice when combined with a current cancer drug, according to researchers at UT Southwestern Medical Center.

16 May 2005

Genetic biomarker that may improve quality of life during treatment for colorectal cancer

A Mayo Clinic-led study has revealed a genetic biomarker that can predict which patients are most likely to experience unwanted side effects from one of the most commonly used and highly effective chemotherapy regimens designed to treat colorectal cancer.

16 May 2005

Zometa reduces bone loss in patients receiving breast cancer treatment

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).

16 May 2005

Tamoxifen study counters hopes that drug might protect the heart

Despite previous studies hinting at tamoxifen's potential benefit for breast cancer survivors' heart health, California researchers have found that the breast cancer drug does not decrease survivors' risk of heart attack.

15 May 2005

Research findings help predict risk of blood clots in women receiving tamoxifen therapy for breast cancer

New research findings may help physicians determine which women have an increased risk of blood clots when taking tamoxifen for the management of breast cancer, a team led by Dana-Farber Cancer Institute investigators will report at the American Society of Clinical Oncology's annual meeting.

15 May 2005

Black cohosh does not reduce hot flashes in women

Mayo Clinic researchers, working with North Central Cancer Treatment Group (NCCTG) investigators, will present new study findings about treatments to reduce hot flashes in women. The research will be outlined during the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting, May 13-17 in Orlando, Fla.

15 May 2005

Doctors and patients think differently about clinical trials

A survey of patients and physicians regarding clinical trials shows that doctors don't recognize the importance of side effects as a barrier for their patients in deciding about whether to undergo experimental therapy.

15 May 2005

Counting number of endothelial cells in blood may predict cancer treatment's effectiveness

Counting the amount of a type of normal cell circulating in the blood of people with cancer could predict whether a tumor progresses or responds to therapy, a new study led by the University of Michigan Comprehensive Cancer Center has found. The finding could give doctors an early indication of whether a treatment will be successful, sparing patients months of an ineffective therapy.

15 May 2005

First advance in pancreatic cancer treatment in a decade offers new hope

The first advance in pancreatic cancer treatment in a decade has been achieved by researchers in a Canadian-led study, and at last gives some encouragement to scientists and invigorates a field that has experienced more than its share of disheartening failures.

15 May 2005

Researchers develop promising new gene network analysis method

Compared with a long-used linear model, a correlation-based statistical method is a more reliable way to map complex gene interactions and pinpoint genes that may be potential cancer treatment targets, according to new Brown University research.

8 May 2005

Fusing physics with medicine to fight cancer

Everyone’s lives are touched by cancer - it is a disease that affects 1 in 3 of us throughout our lifetime. Future developments that lead to earlier diagnosis and more effective therapy lie in further successful collaboration between high energy physicists and the healthcare industry.

2 May 2005

Blocking the COX-1 enzyme might be the answer in ovarian cancer treatment

Researchers at Vanderbilt University Medical Center in a new report say that blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer.

2 May 2005

Cancer treatment - timing is everything

Research led by a cancer biologist at The Cleveland Clinic Lerner Research Institute has identified a molecular mechanism that links the body's internal clock to daily variations in how a patient responds to cancer treatment.

28 Apr 2005

National clinical trial examines new option for kidney cancer patients

The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.

27 Apr 2005

Herceptin in combination with chemotherapy reduces risk of breast cancer recurrence in women with with early-stage breast cancer

Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.

26 Apr 2005